Background. Bacteriuria contributes to antibiotic overuse through treatment of asymptomatic bacteriuria (ASB) and long durations of therapy for symptomatic urinary tract infections (UTIs), yet large-scale evaluations of bacteriuria management among inpatients are lacking.
Urinary tract infections (UTIs) are the fourth most common healthcare-associated infection in the United States and account for more than 12% of infections reported by acute care hospitals [1, 2] . Diagnosis of UTIs is multidimensional involving the combination of signs and symptoms, urinalysis (UA) findings, and urine culture results where available. Recommended antibiotic management for UTIs differs depending on diagnostic category and patient specific characteristics; therefore, accurate diagnosis is imperative. Data suggest urine cultures are frequently ordered without clear indication, leading to misclassification of asymptomatic bacteriuria (ASB) as UTI and subsequent unnecessary antibiotic therapy [3] . A recent cross-sectional evaluation of antibiotic use in US hospitals found 17% of all antibiotics prescribed for infection were given for UTIs [4] . Review of a subset of these antibiotic courses found prescribing for UTIs could be improved in 40% of cases, predominantly due to misclassification of ASB as UTIs [5] .
Treatment of ASB has been evaluated in numerous populations with prospective studies consistently showing no benefit aside from treatment of ASB in pregnant patients and those undergoing genitourinary procedures with anticipated mucosal bleeding [1] . Despite clinical practice guidelines discouraging treatment of ASB outside these populations, nearly two-thirds of patients with ASB receive antibiotics [6] . Treatment only increases risk of harm in the form of selection for antibiotic resistant bacteria, Clostridium difficile infection (CDI), adverse drug events, and may increase risk of subsequent symptomatic UTIs [7, 8] .
Although duration of therapy for symptomatic UTIs differs based on severity, location (i.e., upper vs. lower urinary tract), response to therapy, and the choice of antibiotic agents, available clinical evidence and expert opinion support the shortest duration of therapy appropriate for UTIs in order to minimize antibiotic resistance and adverse reactions. Optimal treatment duration for acute uncomplicated cystitis and pyelonephritis in noncatheterized women is well defined [9, 10] . Duration of therapy for UTIs in men is less well defined; however, recent data suggest similar recurrence rates for outpatient males receiving ≤7 days versus longer durations [7] . Retrospective evaluation of diagnosis and treatment of UTIs at one Veterans Affairs (VA) medical center found not only were diagnostic errors common, but inappropriate duration of treatment was also observed in 43% of outpatients with UTIs [11] .
With rising rates of antibiotic resistant organisms and CDIs, eliminating unnecessary antibiotic use is imperative. Given their frequent contribution to antibiotic use, accurate diagnosis and management of UTIs is essential. With these goals in mind, we aimed to evaluate the current state of inpatient bacteriuria management in the VA Health Care System and assess its consistency with practice guideline recommendations. Specifically, we sought to evaluate the frequency of treatment of ASB, factors associated with treatment of ASB, commonly used durations of therapy, and frequency of complications.
METHODS

Design, Setting, and Participants
The Veterans Health Administration (VHA) is the largest integrated healthcare system in the United States, with 152 VA medical centers providing care to approximately half a million hospitalized veterans annually. We conducted a retrospective medication use evaluation (MUE) of the management of bacteriuria from 1 October 2013 to 30 September 2014, across 25 inpatient VA medical centers that volunteered to participate in this project. We identified patients residing on acute care units with positive urine cultures during or 1 day prior to inpatient admission. Only the first positive urine culture collected during the index admission was evaluated. For patients with multiple admissions with positive urine cultures within the study period, only the earliest hospitalization was evaluated. Patients were excluded if they met any of the following criteria: (1) died within 5 days of urine culture collection date; (2) were transferred to another acute care facility within 5 days of urine culture; (3) urine cultures collected for screening purposes in patients scheduled to undergo urologic intervention within 2 weeks of urine culture date, or in patients who were pregnant; (4) urine culture contained Candida spp. alone or in combination with any other organisms; or (5) had any of the following conditions/ diagnoses as active problems: epididymitis and/or orchitis, prostatitis, severe immunosuppression, spinal cord injury, ileal conduit, or other diversionary surgeries post cystectomy, urinary stents, and polycystic kidney disease.
Objectives and Outcomes
The primary objectives of the MUE were to determine: (1) the proportion of positive urine cultures due to ASB, (2) the number of inpatients with ASB treated with antibiotics excluding non-UTI indications, and (3) the number of inpatients with symptomatic UTIs who are treated with antibiotics for an appropriate duration of therapy based on clinical practice guidelines. Additionally, we evaluated complication rates in all patients with ASB who did and did not receive antibiotic therapy. Complications evaluated included: (1) rates of CDI within 28 days of discharge, (2) [1, 12, 13] . Symptoms consistent with noncatheter associated cystitis included urinary frequency, urgency, dysuria, and/or suprapubic pain. Signs and symptoms consistent with pyelonephritis included fever (>38°C) and at least 1 additional sign or symptom including flank pain or costovertebral angle (CVA) tenderness on physical examination. Signs and symptoms of catheter-associated urinary tract infection (CA-UTI) were defined as fever (>38°C), rigors, flank pain, CVA tenderness, acute hematuria, and/or pelvic discomfort. To meet diagnostic criteria for acute cystitis, a patient was required to have 1 consistent sign or symptom in addition to evidence of urinary tract inflammation on UA (positive leukocyte esterase or pyuria), or 2 consistent signs or symptoms if no UA was collected. To meet diagnostic criteria for CA-UTI, a patient must have 1 consistent sign or symptom in addition to an indwelling urinary catheter on the date of urine culture collection. To meet diagnostic criteria for pyelonephritis, patients were required to have fever and at least 1 sign or symptom consistent with pyelonephritis. ASB was defined as a positive urine culture in the absence of signs or symptoms consistent with a symptomatic UTI. The same definitions were used for all patients regardless of age.
Appropriate treatment and durations of therapy for ASB, uncomplicated cystitis, pyelonephritis and CA-UTI were adapted from IDSA practice guidelines [1, 7, 9, 12] . Treatment for ASB was considered inappropriate and not in accordance with guideline recommendations. For acute cystitis, pyelonephritis in the absence of a urinary catheter and CA-UTIs, ≤7 days was considered appropriate therapy for patients not meeting SIRS criteria. Durations ≤14 days of therapy were considered appropriate for patients who met SIRS criteria on the date of urine culture.
Patients were evaluated for complications including CDI, readmission, and all-cause mortality within 28 days post-discharge. The presence of CDI was defined by the presence of a positive stool laboratory identification for C. difficile including a nonduplicate test result for toxin A and/or B via enzyme immunoassay, or a toxin-producing C. difficile organism detected by culture or polymerase chain reaction.
Data Collection and Analysis
Urine culture and antibiotic susceptibility data, patient demographics, co-morbidities, 28-day all cause mortality, and 28-day readmission rates were collected from the corporate data warehouse by the VA Center for Medication Safety (VAMedSAFE) within VA Pharmacy Benefits Management Services (PBM) in collaboration with the VA Salt Lake City Informatics DecisionEnhancement and Analytic Sciences Center (IDEAS 2.0). A list of patients with urine cultures was given to local facility participants who screened potential cases for inclusion and exclusion criteria and proceeded to full chart review where appropriate. Local facility participants who performed chart review were predominantly clinical pharmacists or pharmacy residents. Systematic chart review involved the use of a standardized data collection tool with supplementary instructions and 2 physician investigators (E. S. and M. G.) were available for questions. Data were entered into case report forms in a secure PBM database via standardized InfoPath forms.
Criteria were developed to identify four subcategories of patients based on retrospective chart review: (1) persons not receiving antibiotics after urine culture, (2) persons receiving antibiotics only for suspected UTI, (3) persons receiving antibiotics for suspected UTI and another non-UTI indication, and (4) persons receiving antibiotics only for a non-UTI indication. Principal analyses were conducted in persons lacking non-UTI indications for antibiotics. Given many clinicians treat patients with bacteriuria meeting SIRS criteria in the absence of specific urinary tract symptoms, we further stratified patients with ASB into those with and without 2 or more SIRS criteria. Descriptive statistics were used to compare clinical characteristics and outcomes between patients with ASB and symptomatic UTIs who did and did not receive antibiotics. Comparisons were performed with χ 2 The final analytical cohort after excluding patients receiving antibiotics for non-UTI indications included 1527 patients (Figure 1 ). Fifty-seven percent (691/1219) of patients receiving antibiotics were classified as ASB. Seventy-two percent (691/961) of patients with ASB received antibiotic therapy (Table 2) . Sixty-eight percent (494/729) of those with ASB who did not meet 2 or more SIRS criteria received antibiotic therapy. The most commonly reported symptoms among patients with ASB who did not meet SIRS criteria yet were treated with antibiotics were altered mental status (29%), lethargy (17%), and malaise (13%). Fifty-seven percent (545/961) of patients with ASB had an unclear rationale for a urine culture either because the provider documented a lack of specific signs or symptoms consistent with a UTI (n = 248), or the provider did not document presence or absence of signs and symptoms (n = 297). Compared to those not receiving antibiotics, patients with ASB who did not meet SIRS criteria yet received antibiotics tended to be older (mean age [SD], 76 [11.6] vs. 72 [12. 0], antibiotics vs. no antibiotics, respectively, P < .01), have documentation of nonlocalizing symptoms including altered mental status, lethargy and malaise (Table 2) . Additionally, these patients were more likely to have a positive leukocyte esterase and/or pyuria (86% vs. 62%, P < .01), positive nitrite on UA (31% vs. 18%, P < .01) and bacteriuria with Escherichia coli (38% vs. 28%, P = .01).
Among patients who received antibiotics only for a suspected UTI, the mean (+/-SD) days of therapy for ASB, cystitis, CA-UTI, and pyelonephritis were 10.0 (4.5), 11.4 (4.7), 12.0 (6.1), and 13.6 (5.3), respectively (Table 3 ). Additionally, 14% of patients with ASB, 20% with cystitis, 28% with CA-UTI, and 52% with pyelonephritis received greater than 14 days of antibiotic therapy. Fluoroquinolones were the most frequently used empiric agent in patients with ASB (245/691 [36%]) and the most commonly prescribed antibiotic at discharge for both patients with ASB (246/485, 50.7%) and symptomatic UTIs (256/458, 55.9%).
The rate of CDI within 28 days discharge was 1.3% versus 0.7% (P = .46) for patients who received antibiotics for ASB as compared to those who did not. There was a nonsignificant trend toward higher readmission rates (9.6% vs. 6.3%, P = .11) and all-cause mortality (7.0% vs. 4.8%, P = .22) within 28 days from index urine culture for patients who received antibiotics for ASB compared to those who did not. Similar nonsignificant trends were seen when stratified by ASB with and without 2 or more SIRS criteria (Table 2 ).
DISCUSSION
Our evaluation of over 2000 cases of bacteriuria among inpatient Veterans demonstrates nearly two-thirds of bacteriuria is asymptomatic, and nearly 70% of patients with ASB who do not meet SIRS criteria are treated with antibiotics. Additionally, durations of therapy for symptomatic UTIs exceed guideline recommendations in the majority of cases, with fluoroquinolones the leading antibiotic class prescribed for empiric and definitive therapy. Similar trends in inappropriate treatment of ASB have been found across various inpatient settings [14] [15] [16] [17] [18] ; however, to the best of our knowledge, our findings represent the largest evaluation of bacteriuria among adult inpatients to date.
Our findings of frequent lack of rationale for urine cultures, as well as the association of treatment of ASB with older age, nonspecific symptoms, pyuria, and certain bacterial species on urine culture confirm others findings [17, 19] . Clinicians often respond to positive cultures but seem particularly influenced by these factors, tipping the scales toward guideline-discordant decision making. These are the cognitive-biases, which if addressed, will likely lead to greatest reductions in antibiotic use for ASB.
The optimal treatment duration for acute uncomplicated cystitis and pyelonephritis in noncatheterized women is well defined [9, 10] . On the contrary, data regarding the optimal duration of treatment for UTI in men is limited, with no specific recommendations within guidelines. Conventional practice for male UTIs is 7 to 14 days of antibiotic therapy; however, comparative trials to define optimal treatment duration for UTI in men are lacking. Drekonja and colleagues performed a retrospective review of over 30 000 outpatient male Veterans with UTIs, finding no significant differences in early or late recurrence between those receiving a shorter duration (≤7 days) versus longer duration (> 7 days) [7] . In addition, risk of CDI was higher with longer duration compared to shorter-duration treatment (0.5% vs. 0.3%, P = .02). In our predominantly male cohort, 85% of patients with cystitis received >7 days of therapy, and 20% received >14 days of therapy. Over half of patients with pyelonephritis received >14 days of therapy despite randomized controlled trial data supporting durations as short as 5-7 days [20, 21] . These findings underscore the critical need for more data and guidance on the shortest effective duration for male UTIs, as well as interventions to reduce unnecessary long antibiotic courses.
Limitations of our evaluation include its retrospective study design with the possibility providers did not document localizing symptoms of a UTI when present, thus contributing to an overestimation of ASB. Additionally, our definition of symptomatic UTI required specific urinary tract symptoms and one could argue that patients meeting SIRS criteria alone warrant antibiotic therapy. However, when patients were stratified by SIRS criteria, a large proportion of patients with ASB not meeting SIRS criteria still received unnecessary treatment. The lack of rationale for urine culture ordering may have been inflated due to lack of provider documentation. We only evaluated presence of a urinary catheter on the date of urine culture collection possibly leading to misclassification of some patients as cystitis thereby contributing to the length of therapy we observed for this group. The attribution of non-UTI indications was not standardized and relied on clinical documentation, potentially overestimating the prevalence of ASB. Finally, our population is predominantly male, and we excluded immunocompromised patients and those with complicated urologic conditions, potentially limiting the applicability of our findings to other populations. However, similar observations have been seen in smaller scale evaluations among comparable patient populations [11, 22] . Our findings have important implications for growing antimicrobial stewardship efforts. As antimicrobial stewardship programs expand in the face of limited resources, our data suggest focusing on bacteriuria can make significant improvements in antibiotic use. Rather than traditional stewardship interventions involving post-prescription audit and feedback to providers, earlier interventions aimed at reducing unnecessary testing and improving diagnostic accuracy will likely prove beneficial. As an example, Leis and colleagues hypothesized clinicians often have low suspicion of UTIs at the time urine cultures are ordered; however, when presented with positive urine cultures, they reflexively order antibiotics despite lack of clinical suspicion for infection [6] . To test their hypothesis, they suppressed urine culture results and asked clinicians to call for results if a UTI was suspected. Modified reporting of urine cultures decreased treatment of ASB by 36% (48% vs. 12%, 95% CI, 15%-57%; P = .002), with no adverse outcomes or episodes of untreated infection. Trautner and colleagues evaluated the impact of a multifaceted intervention including a diagnostic algorithm for CA-UTI and ASB, case-based audit and feedback to providers and provider education [23] . Their intervention resulted in reductions in urine culture ordering (41.2 to 23.3 per 1000 bed-days; incidence rate ratio [IRR], 0.57; 95% CI 0.53-0.61) and unnecessary treatment of ASB (1.6 to 0.6 per 1000 beddays; IRR, 0.35; 95% CI, 0.22-0.55). Based on our evaluation, the VA Antimicrobial Stewardship Task Force produced and disseminated clinical guidance documents and tools for differentiating ASB from symptomatic UTIs, and guidelines for promoting appropriate durations of therapy. These tools were provided to stewardship programs for local adaptation and distribution.
In conclusion, we found the majority of patients with ASB are treated with antibiotics, often broad-spectrum agents for long durations. Additionally, symptomatic UTIs are commonly treated with longer durations of therapy than recommended. The overuse of fluoroquinolones is of particular concern given risk of complications. Rather than reactive antimicrobial stewardship strategies, proactive comprehensive interventions aimed at reducing unnecessary testing and diagnostic bias, and efforts to guide appropriate durations of therapy for symptomatic UTIs will likely prove most beneficial. Additional evaluations of strategies aimed at reducing diagnostic inaccuracy are imperative to halt unnecessary antibiotic use. 
Notes
